A Cleveland Clinic study shows that semaglutide and tirzepatide—injectable GLP-1 drugs for obesity—produce smaller weight ...

Eli Lilly (LLY) will acquire Verve Therapeutics (VERV) for up to $13.5/share, aiming to revolutionize cholesterol treatment.

B Verve Therapeutics (VERV) acquisition offers investors a 70%+ premium. See why I think this deal is beneficial to both ...

A Cleveland Clinic study shows that semaglutide and tirzepatide – injectable GLP-1 drugs for obesity – produce smaller weight ...

Semaglutide (sold under the brand names Wegovy and Ozempic) and tirzepatide (sold under the brand names Zepbound and Mounjaro ... (glycemic control) in a real-world setting.

Eli Lilly ( LLY 0.90%) is one of the undisputed leaders in the fast-growing market for weight-management medicines. Following ...

Lastly, the researchers observed that while patients who discontinued obesity medications lost significantly less weight ...

The SURMOUNT-5 trial, a Phase 3b open-label clinical trial, examined the safety and efficacy of ... “In real-world terms, that means many patients on Zepbound are losing more weight than those ...

In the real world, the use of semaglutide (Wegovy) and tirzepatide (Zepbound) produce far less ... which confirms the efficacy of this medications for the prevention of type 2 diabetes but also ...